Si-Bone Stock Price, News & Analysis

SI-BONE, a medical device company, announced a virtual surgeon panel led by CEO Jeffrey Dunn on October 8, 2020, from 10am to 11am ET. The panel will feature renowned experts discussing the treatment of sacroiliac joint dysfunction and the role of telehealth in surgery.

Panelists include Dr. Peter Whang from Yale, Dr. Bharat Desai from Panorama Orthopedics, Dr. William Tobler from Mayfield Clinic, and Dr. Robert Eastlack from Scripps Health. Interested attendees can register through SI-BONE’s investor relations website.

SI-BONE, a leader in medical devices for musculoskeletal disorders, announced its participation in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference and 2020 Cantor Global Healthcare Conference. Management will present at a Fireside Chat on September 15, 2020, at 5:00 p.m. ET and September 16, 2020, at 12:20 p.m. ET. Interested parties can access the live and archived webcasts on the company's website. The company is known for its iFuse Implant System, designed for minimally invasive SI joint fusion, supported by extensive clinical studies.

SI-BONE, Inc. (Nasdaq:SIBN) reported Q2 2020 financial results, with revenue of $14.0 million, a 14% decrease year-over-year. U.S. revenue totaled $13.2 million, down 12%. International revenue fell by 36% to $0.8 million, largely due to COVID-19's impact on surgical volumes. The company completed a $40 million debt refinancing and received positive coverage from Aetna, covering over 22 million members. The gross margin decreased to 85% from 90%, and the net loss widened to $12.5 million or $0.44 per diluted share. Guidance for 2020 remains withdrawn amid ongoing uncertainty.

SI-BONE, a medical device company focused on sacropelvic disorders, announced its participation in the 40th Annual Canaccord Genuity Growth Conference. The company will conduct a live Fireside Chat on August 12, 2020, at 1:00 p.m. ET. Interested individuals can access the webcast via the company's website. SI-BONE's iFuse Implant System, designed for minimally invasive sacroiliac joint fusion, is supported by multiple clinical studies demonstrating its effectiveness in treating chronic low back pain. The device has been commercially available since 2009 and is covered by various insurance payors.

SI-BONE, Inc. (Nasdaq: SIBN) will announce its Q2 2020 financial results post-market on August 3, 2020. The management team will host a conference call at 1:30 PM PT, accessible via the company’s website. SI-BONE specializes in minimally invasive surgical solutions for sacropelvic disorders, notably through its iFuse Implant System, which addresses chronic low back pain. Supported by numerous clinical studies, the iFuse Implant is the only SI joint fusion device with established insurance coverage for the procedure. Detailed company and product information can be found on their website.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company in California, has successfully re-financed its existing $40 million credit facility. The new five-year term loan, secured through Solar Capital Partners, features an interest rate of 9.40% plus the greater of the 1-month LIBOR Rate or 0.33%. This strategic move will enhance SI-BONE's balance sheet and provide improved operating flexibility. The new loan includes a 36-month interest-only period followed by 24 months of amortization. The refinancing indicates the company's strong operational performance and dedicated team.

SI-BONE, Inc. announces that Aetna has established a positive coverage policy for the iFuse Implant System to treat sacroiliac joint dysfunction. Effective May 28, 2020, this policy grants over 22 million Aetna members access to the minimally invasive SI joint fusion when deemed medically necessary. This decision is supported by extensive clinical evidence, including 5-year results from a prospective study. SI-BONE highlights that the iFuse procedure is crucial for patients suffering from SI joint pain, enhancing accessibility and treatment adoption.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company, will participate in the Bank of America Securities 2020 Health Care Conference on May 13, 2020. The management team will conduct a live Fireside Chat at 8:40 a.m. PT / 11:40 a.m. ET, accessible via the company's website. SI-BONE specializes in minimally invasive surgery for sacroiliac joint disorders with its iFuse Implant System, which has shown significant clinical benefits in treating chronic low back pain. The company emphasizes the importance of their research-backed device in enhancing patient outcomes.

SI-BONE, Inc. (Nasdaq:SIBN) reported Q1 2020 revenue of $16.8 million, marking a 12% increase year-over-year. U.S. revenue reached $15.3 million, a 14% rise, despite lower case volumes in late March due to COVID-19. Gross margin stood at 89%, down from 90% in 2019, while operating expenses rose 20% to $26.8 million. The net loss was $12.8 million, or $0.47 per diluted share, compared to $9.3 million in the same period last year. The company has withdrawn its 2020 guidance due to COVID-19 uncertainties.